GSK-3β Inhibition with Elraglusib Shows Selective Activity and Biomarker Potential in Salivary Gland and Pancreatic Cancers
Clinical trials evaluate elraglusib, a GSK-3β inhibitor, in salivary gland and pancreatic cancers. While results were mixed, findings highlight the importance of nuclear GSK-3β expression as a biomarker and the need for dose optimization to manage combination toxicities.